Methylenedioxymetamfetamine - PharmaTher
Alternative Names: 3,4-methylenedioxy-methamphetamine - PharmaTher; MDMA - PharmaTherLatest Information Update: 01 Apr 2022
At a glance
- Originator PharmaTher
- Class Amines; Amphetamines; Anxiolytics; Behavioural disorder therapies; Benzodioxoles; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Mental disorders
Most Recent Events
- 05 Jan 2022 Preclinical trials in Mental disorders in Canada (Transdermal) as of January 2022 (PharmaTher pipeline, January 2022)
- 14 Dec 2021 Methylenedioxymetamfetamine is available for licensing as of 14 Dec 2021. https://www.pharmather.com/contact.html
- 14 Dec 2021 PharmaTher plans clinical studies in Mental disorders in 2022